(Q36129110)

12 August 2017

1 reference

title

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes (English)

1 reference

12 August 2017

1 reference

Loretta L Nielsen

1

1 reference

12 August 2017

language of work or name

1 reference

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

10

1 reference

12 August 2017

page(s)

703-710

1 reference

Postprandial blood glucose. American Diabetes Association

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

First-phase insulin secretion: does it exist in real life? Considerations on shape and function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903460-4

7 January 2021

10.1016/S1359-6446(05)03460-4

Identifiers

DOI

1 reference

12 August 2017

1 reference